סלולר אינטליג'נס חותמת על הסכם עם נובו נורדיסק לקידום טיפול תאי בפרקינסון

הערכה

A small Israeli biotech has secured a partnership with one of the world's largest drugmakers, signaling growing confidence in cell-based approaches to Parkinson's disease. The deal validates the scientific platform and provides financial runway for early-stage trials. The key question is whether this therapy can overcome the manufacturing and delivery hurdles that have stalled similar programs.